{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:21:11Z","timestamp":1789608071638,"version":"build-2803163510"},"reference-count":58,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Cyclosporine is a selective calcineurin inhibitor used, among other areas, in pediatric gastroenterology as rescue therapy in the treatment of severe ulcerative colitis (ASUC\u2014acute severe ulcerative colitis) in children. The introduction of systemic glucocorticosteroids (GCSs) has significantly reduced mortality in ASUC. However, it should be emphasized that long-term use of these drugs is limited due to the high risk of adverse effects observed during therapy and their limited efficacy. The role of cyclosporine as a second-line therapy is referred to as a \u2018rescue therapy,\u2019 which aims to alleviate the symptoms of ASUC, often avoiding life-threatening complications (including toxic megacolon) and postponing the need for urgent colectomy. If colectomy is necessary, this provides time to better prepare the patient nutritionally and psychologically for surgery and to await the effect of slower-acting thiopurine preparations or other chronic treatments; their effectiveness in achieving long-term clinical and endoscopic remission is limited. New therapeutic approaches include cyclosporine as an inducer, which acts as a bridge to new forms of therapy, such as biological drugs, which are used as maintenance preparations in patients. In pediatric patients, there is limited research in the literature on new strategies for the use of cyclosporine. The aim of this review is to assess current evidence on cyclosporine as induction or rescue therapy in pediatric ASUC and explore future integration with biologic and biosimilar strategies, emphasizing its evolving role as a bridging agent toward biologics and novel targeted therapies.<\/jats:p>","DOI":"10.3390\/jcm14238273","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T11:04:31Z","timestamp":1763723071000},"page":"8273","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Role of Cyclosporine in the Treatment of Severe Ulcerative Colitis in the Pediatric Population: A Narrative Review Exploring Known Strategies and New Possibilities"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4694-7139","authenticated-orcid":false,"given":"Anna","family":"Dancewicz","sequence":"first","affiliation":[{"name":"2nd Clinical Department of Paediatrics, Gastroenterology and Nutrition, Wroclaw Medical University, 50-369 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6495-5995","authenticated-orcid":false,"given":"Katarzyna","family":"Akutko","sequence":"additional","affiliation":[{"name":"2nd Clinical Department of Paediatrics, Gastroenterology and Nutrition, Wroclaw Medical University, 50-369 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4781-4151","authenticated-orcid":false,"given":"Hubert Pawe\u0142","family":"Szyller","sequence":"additional","affiliation":[{"name":"Student Scientific Group of Pediatric Gastroenterology and Nutrition, Wroclaw Medical University, 50-369 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Augustynowicz","sequence":"additional","affiliation":[{"name":"Student Scientific Group of Pediatric Gastroenterology and Nutrition, Wroclaw Medical University, 50-369 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7609-8479","authenticated-orcid":false,"given":"Tomasz","family":"Pytrus","sequence":"additional","affiliation":[{"name":"2nd Clinical Department of Paediatrics, Gastroenterology and Nutrition, Wroclaw Medical University, 50-369 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/ecco-jcc\/jjad004","article-title":"Rescue Therapies for Steroid-refractory Acute Severe Ulcerative Colitis: A Review","volume":"17","author":"Gisbert","year":"2023","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1053\/j.sempedsurg.2017.10.004","article-title":"Very early onset inflammatory bowel disease","volume":"26","author":"Moran","year":"2017","journal-title":"Semin. Pediatr. Surg."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1053\/gast.2001.22122","article-title":"Inflammatory bowel disease: Immunodiagnostics, immunotherapeutics, and ecotherapeutics","volume":"120","author":"Shanahan","year":"2001","journal-title":"Gastroenterology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0016-5085(98)70381-6","article-title":"Inflammatory bowel disease: Etiology and pathogenesis","volume":"115","author":"Fiocchi","year":"1998","journal-title":"Gastroenterology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1463-1318.2008.01682.x","article-title":"The management of acute severe colitis: ACPGBI position statement","volume":"10","author":"Brown","year":"2008","journal-title":"Color. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/MPG.0000000000002036","article-title":"Management of Paediatric Ulcerative in Colitis, Part 2: Acute Severe Colitis-An Evidence-based Consensus Guideline from the European Crohn\u2019s and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition","volume":"67","author":"Turner","year":"2018","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_7","first-page":"97","article-title":"Post\u0119py w terapii nieswoistych zapale\u0144 jelit u dzieci","volume":"5","year":"2013","journal-title":"Gastroenterol. Klin."},{"key":"ref_8","first-page":"46","article-title":"Steroidooporno\u015b\u0107 i steroidozale\u017cno\u015b\u0107 w nieswoistych chorobach zapalnych jelit","volume":"7","author":"Radwan","year":"2015","journal-title":"Gastroenterol. Klin."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cgh.2006.09.033","article-title":"Response to corticosteroids in severe ulcerative colitis: A systematic review of the literature and a meta-regression","volume":"5","author":"Turner","year":"2007","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/ibd.21383","article-title":"Acute severe ulcerative colitis in children: A systematic review","volume":"17","author":"Turner","year":"2011","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/BF01973261","article-title":"Biological effects of cyclosporin A: A new antilymphocytic agent","volume":"6","author":"Borel","year":"1976","journal-title":"Agents Actions"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1196\/annals.1361.110","article-title":"Rationale for T cell inhibition by cyclosporin A in major autoimmune diseases","volume":"1051","author":"Ferraccioli","year":"2005","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1462399400001769","article-title":"Molecular targets for existing and novel immunosuppressive drugs","volume":"2","author":"Stepkowski","year":"2000","journal-title":"Expert. Rev. Mol. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/0140-6736(91)92302-I","article-title":"First-pass metabolism of cyclosporin by the gut","volume":"338","author":"Kolars","year":"1991","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/S0041-1345(99)00085-8","article-title":"Bioequivalence criteria for cyclosporine","volume":"31","author":"Johnston","year":"1999","journal-title":"Transplant. Proc."},{"key":"ref_16","first-page":"7","article-title":"Zastosowanie cyklosporyny w dermatologii","volume":"2","author":"Ryan","year":"2011","journal-title":"Dermatol. Po Dyplomie"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1468-3083.2009.03389.x","article-title":"European S3-guidelines on the systemic treatment of psoriasis vulgaris","volume":"23","author":"Pathirana","year":"2009","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1166\/jbn.2011.1278","article-title":"Nanoparticulate delivery can improve peroral bioavailability of cyclosporine and match Neoral Cmax sparing the kidney from damage","volume":"7","author":"Ankola","year":"2011","journal-title":"J. Biomed. Nanotechnol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3797\/scipharm.0908-12","article-title":"Cyclosporine a-nanosuspension: Formulation, characterization and in vivo comparison with a marketed formulation","volume":"78","author":"Nakarani","year":"2010","journal-title":"Sci. Pharm."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1097\/01.mpg.0000256267.06729.91","article-title":"Efficacy and safety of cyclosporine in the treatment of IBD in children: Retrospective analysis","volume":"43","author":"Socha","year":"2006","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10238-025-01558-6","article-title":"Biosimilars versus biological therapy in inflammatory bowel disease: Challenges and targeting strategies using drug delivery systems","volume":"25","author":"Aljabri","year":"2025","journal-title":"Clin. Exp. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"8979","DOI":"10.3390\/ijms15058979","article-title":"Transition from cyclosporine-induced renal dysfunction to nephrotoxicity in an in vivo rat model","volume":"15","author":"Sereno","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Gooch, J.L., King, C., Francis, C.E., Garcia, P.S., and Bai, Y. (2017). Cyclosporine A alters expression of renal microRNAs: New insights into cal-cineurin inhibitor nephrotoxicity. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0175242"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1056\/NEJM199406303302601","article-title":"Cyclosporine in severe ulcerative colitis refractory to steroid therapy","volume":"330","author":"Lichtiger","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"ref_25","first-page":"296","article-title":"Combined use of cyclo-sporine and azathioprine or 6-mercaptopurine in pediatric inflammatory bowel disease","volume":"22","author":"Ramakrishna","year":"1996","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/BF02148846","article-title":"Cyclosporine for the treatment of fulminant ulcerative colitis in children. Immediate response, long-term results, and impact on surgery","volume":"38","author":"Treem","year":"1995","journal-title":"Dis. Colon. Rectum"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1046\/j.1365-2036.2002.01308.x","article-title":"The use of ciclosporin in paediatric inflammatory bowel disease: An Italian experience","volume":"16","author":"Barabino","year":"2002","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00423-006-0068-y","article-title":"Role of cyclosporin in pre- venting or delaying colectomy in children with severe ulcerative coli-tis","volume":"392","author":"Castro","year":"2007","journal-title":"Langenbecks Arch. Surg."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S0140-6736(94)90115-5","article-title":"Resolution of cyclosporin-induced gingival hypertrophy with metronidazole","volume":"343","author":"Wong","year":"1994","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.cgh.2008.04.035","article-title":"Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis","volume":"6","author":"Maser","year":"2008","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/ajg.2011.62","article-title":"Successive Treatment with Cyclosporine and Infliximab in Steroid-Refractory Ulcerative Colitis","volume":"106","author":"Leblanc","year":"2011","journal-title":"Am. J. Gastroenterol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1007\/s10620-022-07682-7","article-title":"An Old Bridge to the Newer Biologics: Cyclosporine for Rescue Therapy in Acute Severe Ulcerative Colitis","volume":"67","author":"Ashat","year":"2022","journal-title":"Dig. Dis. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.cgh.2018.08.081","article-title":"Efficacy and Safety of Induction Therapy with Calcineurin Inhibitors in Combination with Vedolizumab in Patients with Refractory Ulcerative Colitis","volume":"17","author":"Pellet","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/MPG.0000000000002035","article-title":"Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline from European Crohn\u2019s and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition","volume":"67","author":"Turner","year":"2018","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","article-title":"3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn\u2019s Disease 2016: Part 1: Diagnosis and Medical Management","volume":"11","author":"Dignass","year":"2017","journal-title":"J. Crohns Colitis"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn\u2019s disease","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/apt.15632","article-title":"Editorial: Calcineurin inhibitors as a bridge to vedolizumab for severe ulcerative colitis","volume":"51","author":"Battat","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1093\/ibd\/izab328","article-title":"A Prospective Trial with Long Term Follow-up of Patients with Severe, Steroid-Resistant Ulcerative Colitis Who Received Induction Therapy with Cyclosporine and Were Maintained with Vedolizumab","volume":"28","author":"Tarabar","year":"2022","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/ibd\/izab106","article-title":"Pyoderma gangrenosum in an ulcerative colitis pediatric patient during vedolizumab therapy successfully treated with oral cyclosporine","volume":"27","author":"Graziano","year":"2021","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1007\/s00384-020-03703-x","article-title":"Efficacy of biosimilar infliximab CT-P13 among inpatients with severe steroid-refractory colitis","volume":"35","author":"Ollech","year":"2020","journal-title":"Int. J. Color. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1756284820954112","DOI":"10.1177\/1756284820954112","article-title":"Successful cyclosporin and ustekinumab combination therapy in a patient with severe steroid-refractory ulcerative colitis","volume":"13","author":"Ganzleben","year":"2020","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.cgh.2022.03.008","article-title":"Efficacy of Induction Therapy with Calcineurin Inhibitors in Combination with Ustekinumab for Acute Severe Ulcerative Colitis","volume":"21","author":"Veyrard","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"17562848231218555","DOI":"10.1177\/17562848231218555","article-title":"Long-term outcomes of cyclosporin induction and ustekinumab maintenance combination therapy in patients with steroid-refractory acute severe ulcerative colitis","volume":"17","author":"Vitali","year":"2023","journal-title":"Therap. Adv. Gastroenterol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e00604","DOI":"10.14309\/crj.0000000000000604","article-title":"Combining Cyclosporine with Ustekinumab in Acute Severe Ulcerative Colitis","volume":"8","author":"Shaffer","year":"2021","journal-title":"ACG Case Rep. J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2021.12.282","article-title":"Twenty-first Century Trends in the Global Epidemiology of Pediatric-Onset Inflammatory Bowel Disease: Systematic Review","volume":"162","author":"Kuenzig","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cgh.2018.07.009","article-title":"Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients with Ulcerative Colitis","volume":"17","author":"Hanauer","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1097\/FTD.0000000000000659","article-title":"Quality Assessment of Dried Blood Spots from Patients With Tuberculosis from 4 Countries","volume":"41","author":"Zuur","year":"2019","journal-title":"Ther. Drug Monit."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/j.cgh.2021.05.038","article-title":"Tofacitinib for biologic-experienced hospitalized patients with acute severe ulcerative col-itis: A retrospective case-control study","volume":"19","author":"Berinstein","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/ecco-jcc\/jjab109","article-title":"Sequential use of high- dose tofacitinib after infliximab salvage therapy in acute severe ul-cerative colitis","volume":"16","author":"Gilmore","year":"2021","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1093\/ibd\/izab181","article-title":"Success of cyclosporin and tofacitinib combination therapy in a patient with severe steroid-refractory ulcerative colitis","volume":"27","author":"Yang","year":"2021","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: Results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1093\/ecco-jcc\/jjad115","article-title":"Upadacitinib Salvage Therapy for Infliximab-Experienced Patients with Acute Severe Ulcerative Colitis","volume":"17","author":"Gilmore","year":"2023","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1007\/s00467-017-3641-4","article-title":"Nephrotoxicity in children with frequently relapsing nephrotic syndrome receiving long-term cyclosporine treatment","volume":"32","author":"Hamasaki","year":"2017","journal-title":"Pediatr. Nephrol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Liu, Y., Yan, C., Zhao, Y., Deng, S., and Zu, J. (2025). The safety of cyclosporine and tacrolimus in pediatric nephrotic syndrome patients. Front. Pediatr., 13.","DOI":"10.3389\/fped.2024.1487441"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1093\/ckj\/sfac200","article-title":"Visit-to-visit variability in blood pressure and kidney disease progression in IgA nephropathy","volume":"15","author":"Tang","year":"2022","journal-title":"Clin. Kidney J."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Sergazy, S., Berikkhanova, K., Gulyayev, A., Shulgau, Z., Maikenova, A., Bilal, R., Terzic, M., Zhumadilov, Z., and Aljofan, M. (2025). Cell-Based Drug Delivery Systems: Innovative Drug Transporters for Targeted Therapy. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26178143"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/23\/8273\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T15:24:37Z","timestamp":1763997877000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/23\/8273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":58,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["jcm14238273"],"URL":"https:\/\/doi.org\/10.3390\/jcm14238273","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]}}}